Инфекционное обострение хронического бронхита: логика выбора оптимального антибиотика

1. Anthonisen N.R., Marifreda J, Warren С.P. et al. Antibiotic therapy in acute exacerbation oi chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.

2. Anzueto A. Contemporary diagnosis and management of bronchitis. 2nd ed. Newtown, Pennsylvania: Handbooks in Health Care Co.; 1999.

3. Aubier М., Lode H., Gialdroni-Grassi G. et al. Spariloxacin for the treatment of community-acquired pneumoniae: a pooled data analysis of two studies. J. Antimicrob. Chemother. 1996; 77 (suppl A): 73-82.

4. Ball P., Wilson R., Mandell L. et al. Gemifloxacin long-term exacerbations in bronchitis (G LO B E ) study In: Programm and abstracts of the 40th Interscience conference on antimicrobial agents and chemotheraby, Toronto; 2000. P. 475, abstr.-812.

5. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption. J. Chemother. 1999; 11 (suppl.): 35-43.

6. Choi E., Lee H. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin. Infect. Dis 1998; 26: 1346-1354.

7. Craig W.A. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 1996; 25: 213-217.

8. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 1996; 15: 255-259.

9. Dagan R., Leibovitz E., Jacobs M. et al. Bacteriologic response to acute otitis media caused by Haemophilus influenzae treated with azithromycin. In: Program and abstract of the 37th Interscience conference on antimicrobial agents and chemotherapy. Toronto; 1997. Abstr. K-102.

10. Dagan R., Piglansky L., Yagupsky P., et al. Bacteriologic response in acute otitis media: comparison between azithromycin, cefaclor, amoxicillin. Ibid. Abstr. K-103.

11. Dagan R., Johnson C.E., McLinn S. et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate versus azithromycin in acute otitis media. Pediatr. Infect. Dis. J. 2000; 19: 95-104.

12. Deeks S.L., Palacio R., Ruinsky R. et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999; 103: 409-413.

13. Drusano G.L., Goldstein F.W. Relevance of the Alexander Project: pharmacodynamic considerations. J. Antimicrob. Chemother. 1996; 38 (suppl. A): 141-54.

14. Drusano G.L., Craig W.A. Relevance of pharmacodynamics and pharmacokinetics in the selection of antibiotics for respiratory tract infections. J. Chemother. 1997; 9 (suppl.3): 38-44.

15. Dudley M.N. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am. J. Med. 1991; 91 (suppl. 6A): 45S-50S.

16. Felmingham D., Reinert. R., Hirakata Y., Rodlofj A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from PRO TECT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 2002; 50 (suppl. 1 ):.25-37.

17. Fujita К., Murono K., Yoshikawa М., Murai T. Decline of erythromycin resistance of group A streptococci in Japan. Pediatr. Infect. Dis. J. 1994; 13: 1075-1078.

18. Garau J., Lonks J.R., Gomez L. et al. Failure of macrolide therapy in patients with bacteriemia due to macrolide resistant Streptococcus pneumoniae. In: 5th International conference on the macrolides, azalides, streptogramins, ketolides and oxazolidinones (ICMAS-KO). Seville; 2000. Abstr. 7.09.

19. Guillemot D., Carbon C., Thibult N. et al. Macrolide use is associated with macrolide resistant (M RSp) and penicillin resistant (PRSp) Streptococcus pneum oniae [abstract]. In: 40th Interscience conference on antimicrobial agents and chemotherapy. Toronto; 2000. 463.

20. Hoban D., Felmingham D. The PRO TECT surveillance study: antimicrobial susceptibility of II.influenzae and M .catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 2002; 50 (suppl. 1): 49-59.

21. Jackson M.A ., Burry V.F., Olson L.C. et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr. Infect. Dis. 1996; 15: 1049-1051.

22. Jacobs M.R., Dagan R., Rose F.V. et al. Correlation of bacteriologic outcome and antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae in acute otitis media treated with amoxicillin-clavuianate and azithromycin. In: 39th Interscience conference on antimicrobial agents and chemotherapy. 1999. 707, abstr. 164.

23. Moxon E.R., Murphy T.F. Haemophilus influenzae. In: Principles and practice of infectious diseases (Vol. II). Eds. G.L. Mandell, J.E.Bennett, R.Dolin. 5th ed. Philadelphia: Churchill Livingstone; 2000. 2369-2378.

24. Murhy T.F., Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 146: 1067-1083.

25. Nicolau D. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J. Antimicrob. Chemother. 2002; 50 (suppl. 1): 61-70.

26. Perez-Trallero E. Pneumococcal macrolide resistance — not a myth. Ibid. 2000; 45: 401-402.

27. Pihlajamaki М., Jalava J., Kaurila T. et al. Makrolide-resistant Streptococcus pneumoniae and antimicrobial consumption [abstract]. 10th European Congress Clin. Microbiol. Infect. Dis. 28-31 May, 2000, Stockholm, Sweden. Clin. Microbiol. Infect. 2000; 6 (suppl. 1): 87.

28. Saint S., Bent S., Vittinghoff E. et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J.A.M .A. 1995; 273: 957-960.

29. Schito G.C., Mannelli S., Pesce A., the Alexander Project Group. Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. J. Chemother. 1997: 9 (suppl.3): 18-28.

30. Seppala H., Nissinen A., Jarvinen H. et al. Resistance to erythromycin in group A streptococci. N. Engl. J. Med. 1992: 326: 292-297.